by Raynovich Rod | Jan 17, 2014 | Biopharmaceuticals
J.P.Morgan Healthcare Conference Update #3 IBB ($248) New High Today at $249.50 Up 9% YTD–Fidelity Select Biotech (FBIOX) New All time High of $205.85 Up 19% since Dec.18!!! Trading Opportunities-Recovery from Bottom or “Dead Cat” Bounce? Achillion...
by Raynovich Rod | Jan 16, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Biotech Rally Continues With IBB ($245) At New Highs-Up 10 Pts. From Monday’s Bottom Several Rayno Life Science picks were up after presentations at the 2014 J.P.Morgan Healthcare Conference. All of our portfolio picks are strong holds unless otherwise noted....
by Raynovich Rod | Jan 14, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
New Highs in Life Science Sector Life Science stocks are in big rally after the strange sell-off yesterday. The IBB hit a new high today at $244 up 3.67%. Most Rayno Life Science picks are up with significant movers: ALKS up 2%, ALXN up 4%, AMGN up 1.1%, BIIB up...
by Raynovich Rod | Jan 10, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Jan 9, 2014 | 2024 Rayno Tools and Diagnostics Portfolio
Two Rayno Laggards Up On Good Volume: RGDX, SQNM The only two losers among our portfolio picks in 2013 are up today. Response Genetics (RGDX $1.32) is up 2.56% on a volume of almost 500k shares with no apparent news. The Company raised $4.8M in December at $1.20 share...
by Raynovich Rod | Jan 7, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Update 1/8/13 Blow-Off anticipating J.P.Morgan Conference? Breakthrough: IBB hit new highs above $230 today. Green screen with most large cap and mid caps. ALKS, BIIB among movers. XBI is also up 2%. Rayno Life Science stocks are in the bullish groove as investors...
by Raynovich Rod | Jan 6, 2014 | Biopharmaceuticals
Celgene (CELG $162) is not on the Rayno biopharmaceutical focus list but it is a good candidate for hedging with a short position or profit taking. Goldman downgraded the stock today from Neutral to SELL . Also, the Wall Street Journal has an article in the...
by Raynovich Rod | Jan 3, 2014 | Life Science ETF's and Mutual Funds
Steady As She Goes The IBB ($226) remains steady in the $225 range in quiet trading through the holiday period. The XBI ($130.69) shows a similar trend near its 52 week high. Fidelity Select Biotech Fund (FBIOX ) is at its one year high of $182.50. As 2014 unfolds we...
by Raynovich Rod | Jan 1, 2014 | Weather//Ski Reports-Western US
Update 12 N 1/23/14 Accuweather is sticking their umbrellas out calling for rain in San Francisco on Feb 4-but today downgraded that forecast. Unisys gives us nothing for six days.Same for NOAA9mh.gif 720×729 pixels Sheckter offers Hope for early Feb as well: Mammoth...